Nahdi Medical Company








→ H1 2025 Financial Highlights

RESILIENT FINANCIAL PERFORMANCE	# (% of revenue)	H1 2025	▲ % of growth	H1 2024
	Revenue	5.16bn	9.1%	4.73bn
	Gross Profit	1.91bn (37.0%)	6.6%	1.79bn (37.9%)
	Operating Profit	531mn (10.3%)	5.1%	505mn(10.7%)
	Net Profit	494mn(9.6%)	2.7%	481mn (10.2%)
	业 (% of revenue)	Q2 2025	▲% of growth	Q2 2024
	Revenue	2.53bn	2.2 %	2.47bn
	Gross Profit	966mn(38.2%)	3.2 %	936mn(37.9%)
	Operating Profit	261mn (10.3%)	V (4.7)%	273mn (11.1%)
	Net Profit	238mn (9.4%)	(3.8)%	248mn (10.0%)
STRONG CASH FLOW GENERATION	Capex 3.7% of revenue	ZERO DEBT	DPS 2.60 (4.0% vs H1 2024) 338mn Dividend Distribut	



Solid Revenue Growth Across Businesses & Categories

Pharmacies	1,120	1,181	1,187	1,207
Clinics	6	10	8	12




Revenue grew by 9.1% YoY in H1 2025, reflecting strong momentum across all business segments.

Retail business rose by 7.3% fueled by continued growth in both Pharma and Front Shop segments.

Healthcare and UAE businesses continued their upward momentum delivering YoY increases of 82.2% & 41.4%, respectively.




Diversified Sales Channel Growth Driving Top-Line Acceleration





Operating Margin Stability Driven By OPEX Efficiencies Compensating For Gross Margin Compression




The margin compression was primarily driven by ongoing investments to support top-line growth and accelerated growth in the Healthcare and online businesses, which operate with different margin profiles.

Higher private label contribution supported a favourable shift in product mix which enabled the company to reinvest behind sales growth.

Profitability was impacted by higher operating expenses driven by accelerated new openings in the Retail & Healthcare businesses and digital investments, which was partially offset by efficiency initiatives.




Best in Class Operating Profit Margin



Source: Company disclosure

Nahdi Medical Company | Q2 2025 EARNINGS CALL

Attractive Net Profit Profile



Net profit grew by 2.7%, reaching # 494 million, representing 9.6% Margin.

Items below operating profit reflected a net increase in expenses of £13 million, primarily to support revenue growth and the accelerated business expansions.

Guidance



2025 Guidance

H1 2025 Actuals

Total revenue Growth

Revenue growth (6% - 8%)

9.1%

EPS

EPS Expected to grow annually at (4% - 6%)

2.7%

Capex

Capex (~4%)

3.7%

Dividend Policy

Expected to continue at (70% - 80%)

87% in FY2024

Zero Debt

Capital Structure

Growth to be funded organically







Invested in the success of our people More than 500K hours of



Always cultivating Saudi talents Strong Partnerships

24 Universities. providing 2,000+ training opportunities 35.5% **Nationalization**

No. 1

Hiring +1000 national pharmacists

Won in Q2 2025



Best Places to Work




the Best Workplaces for Women

LARIN 67% of revenue generated from Nahdi "Nuhdeek" Guests-90 **NPS** As Q1 2025 he brand equity of pharmacies and underlying brand positioning, future store visit consideration, Nahdi Medical Company | Q2 2025 EARNINGS CALL

Nahdi: Guest Satisfaction - the Cornerstone of our strategy


Stronger Brand Equity YoY



Setting Standards, Winning Honors: Nahdi's Global Impact



CEO of the Year across **Asia**



In-store customer experience- KSA



Retail App of the year - KSA



Setting Standards, Winning Honors: Nahdi's Global Impact







مجاس الضمان الصدي مجاس الضمان الصدي Council of Health Insurance Excellence in Primary Care Award Non-Hospital Category



LOYALTY360

- 1. Customer Loyalty
 Transformation Award
- 2. Personalization, Strategy & Innovation Award



1 Gold
3 Silver
Awards for excellence in employee & guest experience



Digital Acceleration: Seamless Experiences to Fuel Nahdi's 2025 Growth

> Clean, natural plant extracts you can trust.




Highest Online contribution

In Q2 2025

25%

vs 23% Q2 2024

Launched Nuhdeek
shop with 100K
items sold





Nahdi's Private Label Powerhouse; Delivering Growth & Guest Loyalty

Exceptional Growth: H1 2025
 Revenue +43% with Revenue
 Contribution 16% vs 12% H1 2024

 Partnered with 8 local medicine manufacturers & introduced 149 total SKUs by H1 2025



Nahdi Medical Company I O2 2025 EARNINGS CALL

Launched **Lab at Home** new service with Wellness cards sales around **# 32M**



Nahdi's Strategic Expansion in UAE; A Robust Platform for Regional Growth



- Strong growth Q2 2025 Revenue 44% vs
 H1 2024 & added 9 new pharmacies
 totaling 34 in UAE
- Broad geographic coverage with presence in all major Emirates, which strengthens our reach
- UAE NPS at 83
- Established Best-in-class distribution center in Dubai Investment Park (DIP)





Trusted by millions for better life choices everyday & everywhere



Thank You

Investor Relations Department

Contacts:

Website: https://investors.nahdi.sa/

Email: <u>IR@nahdi.sa</u>

Phone: +966 556 315 822